董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel C. Croteau | 男 | Lead Independent Director | 59 | 12.10万美元 | 未持股 | 2026-06-04 |
| Joseph John Hassett | 男 | Director | -- | 未披露 | 未持股 | 2026-06-04 |
| Symeria Hudson | 女 | Director | -- | 未披露 | 未持股 | 2026-06-04 |
| R. Jeffrey Bailly | 男 | Executive Chairman of the Board | 63 | 166.54万美元 | 未持股 | 2026-06-04 |
| Thomas Oberdorf | 男 | Director | 67 | 12.40万美元 | 未持股 | 2026-06-04 |
| Marc Kozin | 男 | Director | 63 | 13.60万美元 | 未持股 | 2026-06-04 |
| Cynthia L. Feldmann | 女 | Director | 72 | 13.50万美元 | 未持股 | 2026-06-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher P. Litterio | 男 | General Counsel,Secretary and Senior Vice President of Human Resources | 62 | 44.85万美元 | 未持股 | 2026-06-04 |
| Jason Holt | 男 | Vice President and Chief Commercial Officer | -- | 未披露 | 未持股 | 2026-06-04 |
| R. Jeffrey Bailly | 男 | Executive Chairman of the Board | 63 | 166.54万美元 | 未持股 | 2026-06-04 |
| Ronald J. Lataille | 男 | Senior Vice President,Treasurer and Chief Financial Officer | 63 | 60.96万美元 | 未持股 | 2026-06-04 |
| Mitchell C. Rock | 男 | President and Chief Executive Officer | 58 | 58.98万美元 | 未持股 | 2026-06-04 |
董事简历
中英对照 | 中文 | 英文- Daniel C. Croteau
-
Daniel C. Croteau，担任Vention Medical公司的首席执行官（2011年1月以来）。Vention Medical公司提供一次性医疗器械的组件制造、组装和设计服务，涉及美国、中美洲、爱尔兰和以色列的13个设施。任职Vention Medical公司之前，他曾担任FlexMedical的总裁（2005年7月至2010年12月）。FlexMedical公司是Flextronics公司（为一次性医疗器械、诊断仪器和药物输送设备提供制造和供应链服务）的医疗部门。2004年7月至2005年6月，他曾担任Accellent（于2014年更名为Lake Region Medical，用于骨科、心脏病和手术设备的专业部件和医疗设备的制造商）执行副总裁兼矫形术总经理。从1999年8月到2004年6月，他曾担任MedSource Technologies（于2004年6月与UTI Corporation合并成Accellent）的执行官。作为MedSource Technologies的高级副总裁，他曾负责销售、营销、战略和收购。1999年进入医疗器械行业之前，他的职业生涯中大部分时间担任General Electric的多种职务，也担任Booz & Company（位于澳大利亚悉尼）的顾问。他持有the University of Vermont的机械工程学士学位，以及哈佛大学商学院 （Harvard Business School）的工商管理硕士学位。2014年10月以来，他也曾担任Inventus Power（定制电池、充电和便携式电源系统的私营全球制造商）的董事会成员。
Daniel C. Croteau has served as one of our directors since December 2015. Presently Mr. Croteau is the CEO of Corza Medical, a private equity-backed company that specializes in high performance wound closure products, biosurgical products and surgical knives. Mr. Croteau's prior company, Surgical Specialties Corporation, was acquired in January 2021 and was simultaneously combined with the Tachosil Business from Takeda Pharmaceuticals to form Corza Medical. Corza Medical has a global sales and marketing organization and operates manufacturing facilities in the United States, China, England, Germany, and Mexico. Mr. Croteau was the Chief Executive Officer of Vention Medical from January 2011 until March 2017 when he resigned in connection with the acquisition of Vention Medical by Nordson Corporation and the divestiture of the Vention Device Manufacturing Services business unit to MedPlast Inc. Vention Medical provides component manufacturing, assembly and design services for disposable medical devices, with fourteen facilities across the United States, Central America, Ireland and Israel. Prior to assuming his role with Vention Medical, Mr. Croteau was President of FlexMedical from July 2005 through December 2010. FlexMedical is the medical division of Flex Nasdaq: FLEX, which provides manufacturing and supply chain services for disposable medical devices, medical equipment, and drug delivery devices. From July 2004 to June 2005 Mr. Croteau served as the Executive Vice President and General Manager of Orthopedics for Accellent (renamed Lake Region Medical in 2014 and now a division of Integer), a manufacturer of specialty components and finished medical devices used in orthopedic, cardiology, and surgical devices. From August 1999 to June 2004 Mr. Croteau served as an executive at MedSource Technologies, which was merged in June 2004 with UTI Corporation to form Accellent. As Senior Vice President at MedSource Technologies, Mr. Croteau was responsible for sales, marketing, strategy and acquisitions. Prior to entering the medical device industry in 1999 Mr. Croteau spent the majority of his career in various roles at General Electric, and working as a consultant for Booz & Company in Sydney, Australia. Mr. Croteau has a Bachelor of Science degree in mechanical engineering from the University of Vermont and a Master of Business Administration from Harvard Business School. Since May 2019 Mr. Croteau has served on the board of directors of Resonetics, a privately held laser manufacturing services company providing micro components to global medical device companies. From October 2014 to March 2018 and from July 2020 to present, Mr. Croteau also served as a member of the board of directors of Inventus Power, a privately held, global manufacturer of custom battery packs, chargers and portable power supply systems. - Daniel C. Croteau，担任Vention Medical公司的首席执行官（2011年1月以来）。Vention Medical公司提供一次性医疗器械的组件制造、组装和设计服务，涉及美国、中美洲、爱尔兰和以色列的13个设施。任职Vention Medical公司之前，他曾担任FlexMedical的总裁（2005年7月至2010年12月）。FlexMedical公司是Flextronics公司（为一次性医疗器械、诊断仪器和药物输送设备提供制造和供应链服务）的医疗部门。2004年7月至2005年6月，他曾担任Accellent（于2014年更名为Lake Region Medical，用于骨科、心脏病和手术设备的专业部件和医疗设备的制造商）执行副总裁兼矫形术总经理。从1999年8月到2004年6月，他曾担任MedSource Technologies（于2004年6月与UTI Corporation合并成Accellent）的执行官。作为MedSource Technologies的高级副总裁，他曾负责销售、营销、战略和收购。1999年进入医疗器械行业之前，他的职业生涯中大部分时间担任General Electric的多种职务，也担任Booz & Company（位于澳大利亚悉尼）的顾问。他持有the University of Vermont的机械工程学士学位，以及哈佛大学商学院 （Harvard Business School）的工商管理硕士学位。2014年10月以来，他也曾担任Inventus Power（定制电池、充电和便携式电源系统的私营全球制造商）的董事会成员。
- Daniel C. Croteau has served as one of our directors since December 2015. Presently Mr. Croteau is the CEO of Corza Medical, a private equity-backed company that specializes in high performance wound closure products, biosurgical products and surgical knives. Mr. Croteau's prior company, Surgical Specialties Corporation, was acquired in January 2021 and was simultaneously combined with the Tachosil Business from Takeda Pharmaceuticals to form Corza Medical. Corza Medical has a global sales and marketing organization and operates manufacturing facilities in the United States, China, England, Germany, and Mexico. Mr. Croteau was the Chief Executive Officer of Vention Medical from January 2011 until March 2017 when he resigned in connection with the acquisition of Vention Medical by Nordson Corporation and the divestiture of the Vention Device Manufacturing Services business unit to MedPlast Inc. Vention Medical provides component manufacturing, assembly and design services for disposable medical devices, with fourteen facilities across the United States, Central America, Ireland and Israel. Prior to assuming his role with Vention Medical, Mr. Croteau was President of FlexMedical from July 2005 through December 2010. FlexMedical is the medical division of Flex Nasdaq: FLEX, which provides manufacturing and supply chain services for disposable medical devices, medical equipment, and drug delivery devices. From July 2004 to June 2005 Mr. Croteau served as the Executive Vice President and General Manager of Orthopedics for Accellent (renamed Lake Region Medical in 2014 and now a division of Integer), a manufacturer of specialty components and finished medical devices used in orthopedic, cardiology, and surgical devices. From August 1999 to June 2004 Mr. Croteau served as an executive at MedSource Technologies, which was merged in June 2004 with UTI Corporation to form Accellent. As Senior Vice President at MedSource Technologies, Mr. Croteau was responsible for sales, marketing, strategy and acquisitions. Prior to entering the medical device industry in 1999 Mr. Croteau spent the majority of his career in various roles at General Electric, and working as a consultant for Booz & Company in Sydney, Australia. Mr. Croteau has a Bachelor of Science degree in mechanical engineering from the University of Vermont and a Master of Business Administration from Harvard Business School. Since May 2019 Mr. Croteau has served on the board of directors of Resonetics, a privately held laser manufacturing services company providing micro components to global medical device companies. From October 2014 to March 2018 and from July 2020 to present, Mr. Croteau also served as a member of the board of directors of Inventus Power, a privately held, global manufacturer of custom battery packs, chargers and portable power supply systems.
- Joseph John Hassett
-
Joseph John Hassett，在2024年11月退休之前一直担任亚德诺公司（“ADI”）的高级副总裁兼首席转型官，在此之前，他自2021年8月起担任Maxim业务的高级副总裁兼首席运营官，负责领导ADI的战略和运营重点，以整合ADI于2021年8月收购的价值25亿美元的业务Maxim Inc.。Hassett先生作为商业领袖带来了丰富的经验，他曾经营ADI最大的创收业务，除了在ADI担任的各种工程管理职务外，还利用他以前在全球运营和技术领域的领导地位发挥了运营专长。此前，Hassett先生担任企业整合管理高级副总裁，在那里他领导了并购交易方面的重大努力，并负责制定战略，从2020年12月到2021年7月，推动将数十亿美元的交易从尽职调查整合到完全整合的实体。此前，Hassett先生于2019年11月至2020年12月担任工业和消费者集团高级副总裁，在那里他领导了增长计划，这些计划利用了其在测量、传感和测试方面的广泛特许经营能力。他于2015年5月至2019年11月担任全球运营与技术高级副总裁，在制定和执行UFP Technologies，Inc.制造战略以及创建世界级、可扩展的供应链以为UFP Technologies，Inc.客户提供卓越质量方面发挥了重要作用。Hassett先生于1982年从利默里克大学毕业后加入ADI，在那里他获得了制造工程理学学士学位。Hassett先生还拥有利默里克大学的工商管理硕士学位。
Joseph John Hassett,was Senior Vice President and Chief Transformation Officer for Analog Devices Inc, ("ADI") up to his retirement in November 2024, prior to that he was Senior Vice President and Chief Operating Officer for the Maxim Business since August 2021 where he led ADI's strategic and operational focus to integrate Maxim Inc., a $2.5 billion business acquired by ADI in August 2021. Mr. Hassett hass extensive experience as a business leader having run ADI's largest revenue-generating business, operational expertise leveraging his previous Global Operations & Technology leadership, in addition to his various engineering management roles with ADI. Previously, Mr. Hassett was Senior Vice President, Corporate Integration Management where he led significant efforts in M&A transactions and was responsible for developing strategies that drove the integration of multi-billion-dollar transactions from due diligence to fully integrated entities from December 2020 to July 2021. Previously, Mr. Hassett was Senior Vice President of Industrial and Consumer Group from November 2019 to December 2020 where he led growth initiatives that leveraged its extensive franchise capability in measurement, sensing, and testing. He was Senior Vice President of Global Operations & Technology from May 2015 to November 2019, where he was instrumental in setting and executing Ufp Technologies, Inc. manufacturing strategy and creating a world-class, scalable supply chain to deliver outstanding quality for Ufp Technologies, Inc. customers. Mr. Hassett joined ADI in 1982 after graduating from the University of Limerick where he earned a Bachelor of Science degree in Manufacturing Engineering. Mr. Hassett also holds a Master of Business Administration from the University of Limerick. - Joseph John Hassett，在2024年11月退休之前一直担任亚德诺公司（“ADI”）的高级副总裁兼首席转型官，在此之前，他自2021年8月起担任Maxim业务的高级副总裁兼首席运营官，负责领导ADI的战略和运营重点，以整合ADI于2021年8月收购的价值25亿美元的业务Maxim Inc.。Hassett先生作为商业领袖带来了丰富的经验，他曾经营ADI最大的创收业务，除了在ADI担任的各种工程管理职务外，还利用他以前在全球运营和技术领域的领导地位发挥了运营专长。此前，Hassett先生担任企业整合管理高级副总裁，在那里他领导了并购交易方面的重大努力，并负责制定战略，从2020年12月到2021年7月，推动将数十亿美元的交易从尽职调查整合到完全整合的实体。此前，Hassett先生于2019年11月至2020年12月担任工业和消费者集团高级副总裁，在那里他领导了增长计划，这些计划利用了其在测量、传感和测试方面的广泛特许经营能力。他于2015年5月至2019年11月担任全球运营与技术高级副总裁，在制定和执行UFP Technologies，Inc.制造战略以及创建世界级、可扩展的供应链以为UFP Technologies，Inc.客户提供卓越质量方面发挥了重要作用。Hassett先生于1982年从利默里克大学毕业后加入ADI，在那里他获得了制造工程理学学士学位。Hassett先生还拥有利默里克大学的工商管理硕士学位。
- Joseph John Hassett,was Senior Vice President and Chief Transformation Officer for Analog Devices Inc, ("ADI") up to his retirement in November 2024, prior to that he was Senior Vice President and Chief Operating Officer for the Maxim Business since August 2021 where he led ADI's strategic and operational focus to integrate Maxim Inc., a $2.5 billion business acquired by ADI in August 2021. Mr. Hassett hass extensive experience as a business leader having run ADI's largest revenue-generating business, operational expertise leveraging his previous Global Operations & Technology leadership, in addition to his various engineering management roles with ADI. Previously, Mr. Hassett was Senior Vice President, Corporate Integration Management where he led significant efforts in M&A transactions and was responsible for developing strategies that drove the integration of multi-billion-dollar transactions from due diligence to fully integrated entities from December 2020 to July 2021. Previously, Mr. Hassett was Senior Vice President of Industrial and Consumer Group from November 2019 to December 2020 where he led growth initiatives that leveraged its extensive franchise capability in measurement, sensing, and testing. He was Senior Vice President of Global Operations & Technology from May 2015 to November 2019, where he was instrumental in setting and executing Ufp Technologies, Inc. manufacturing strategy and creating a world-class, scalable supply chain to deliver outstanding quality for Ufp Technologies, Inc. customers. Mr. Hassett joined ADI in 1982 after graduating from the University of Limerick where he earned a Bachelor of Science degree in Manufacturing Engineering. Mr. Hassett also holds a Master of Business Administration from the University of Limerick.
- Symeria Hudson
-
Symeria Hudson，目前，Hudson女士是United Way Miami的总裁兼首席执行官。在担任United Way Miami角色之前，她曾于2018年11月至2022年7月担任Chapman Partnership的首席执行官。自2018年8月以来，Hudson女士担任Revival Healthcare Partners的运营顾问；2021年7月至2024年12月担任MTF Biologics的执行董事会成员以及治理和审计委员会成员；并担任Baxter Foundation的董事会成员。从2016年4月到2018年1月，Hudson女士担任价值18亿美元的国际医疗产品和技术公司ConvaTec的全球特许经营和创新总裁。从2013年12月到2016年3月，Hudson女士在Baxter，Inc.担任各种战略领导职务，该公司是一家价值107亿美元的公司，开发、制造和销售产品，提供广泛的基本肾脏医院产品组合，包括家庭、急性和中心透析；无菌IV解决方案；以及输液系统和设备。在加入百特之前，Hudson女士是Hospira，Inc（现为辉瑞）的持续改进和转型副总裁，该公司是一家价值40亿美元的世界领先企业，在特种仿制药注射药物、仿制药急性护理和肿瘤注射药物、综合输液治疗设备和药物管理解决方案方面处于领先地位。从2005年5月到2013年7月，Hudson女士曾担任药物管理系统总经理、上市产品策略设备全球营销副总裁、市场营销–美国地区药物管理系统副总裁以及持续改进和转型副总裁。1999年8月至2005年2月期间，Hudson女士在怡安担任过各种领导职务，该公司是一家价值80亿美元的风险管理、零售、再保险和批发经纪、索赔管理、专业服务和人力资本咨询服务公司；Household International是一家在美国、英国和加拿大提供消费贷款、信用卡、汽车金融和信用保险产品的价值80亿美元的金融服务提供商。Hudson女士拥有哈佛商学院工商管理硕士学位和阿拉巴马农工大学学士学位。她被公认为2015年度彩色50大商业领袖。
Symeria Hudson,Presently, Ms. Hudson is the President and CEO of United Way Miami. Prior to the United Way Miami role, she served as CEO of Chapman Partnership from November 2018 through July 2022. Since August 2018, Ms. Hudson has served as an Operating Advisor for Revival Healthcare Partners; as an executive Board Member and on the Governance and Audit Committee for MTF Biologics from July 2021 through December 2024 ; and as a Board Member for Baxter Foundation. From April 2016 to January 2018, Ms. Hudson was the President of Global Franchises and Innovation for ConvaTec, a $1.8 Billion international medical products and technologies company. From December 2013 to March 2016, Ms. Hudson served in various strategic leadership roles for Baxter, Inc., a $10.7 billion company that develops, manufactures, and markets products providing a broad portfolio of essential renal hospital products including home, acute and in-center dialysis; sterile IV solutions; and infusion systems and devices. Before joining Baxter, Ms. Hudson was the VP of Continuous Improvement & Transformation for Hospira, Inc (now Pfizer), a $4 billion world leader in specialty generic injectable pharmaceuticals, generic acute-care and oncology injectables, integrated infusion therapy devices and medication management solutions. From May 2005 to July 2013, Ms. Hudson served as General Manager of Medication Management Systems, VP of Global Marketing for On-Market Product Strategies Devices, VP of Marketing – US Region Medication Management Systems, and VP of Continuous Improvement and Transformation. Between August 1999 and February 2005, Ms. Hudson served in various leadership roles for Aon Corporation, an $8 billion risk management, retail, reinsurance & wholesale brokerage, claims management, specialty services, and human capital consulting services company; and Household International, an $8 billion financial service provider of consumer loans, credit cards, auto finance, and credit insurance products in the US, UK, and Canada. Ms. Hudson holds a Master of Business Administration from Harvard Business School and a BS from Alabama A&M University. She was recognized as a Top 50 Business Leader of Color in 2015. - Symeria Hudson，目前，Hudson女士是United Way Miami的总裁兼首席执行官。在担任United Way Miami角色之前，她曾于2018年11月至2022年7月担任Chapman Partnership的首席执行官。自2018年8月以来，Hudson女士担任Revival Healthcare Partners的运营顾问；2021年7月至2024年12月担任MTF Biologics的执行董事会成员以及治理和审计委员会成员；并担任Baxter Foundation的董事会成员。从2016年4月到2018年1月，Hudson女士担任价值18亿美元的国际医疗产品和技术公司ConvaTec的全球特许经营和创新总裁。从2013年12月到2016年3月，Hudson女士在Baxter，Inc.担任各种战略领导职务，该公司是一家价值107亿美元的公司，开发、制造和销售产品，提供广泛的基本肾脏医院产品组合，包括家庭、急性和中心透析；无菌IV解决方案；以及输液系统和设备。在加入百特之前，Hudson女士是Hospira，Inc（现为辉瑞）的持续改进和转型副总裁，该公司是一家价值40亿美元的世界领先企业，在特种仿制药注射药物、仿制药急性护理和肿瘤注射药物、综合输液治疗设备和药物管理解决方案方面处于领先地位。从2005年5月到2013年7月，Hudson女士曾担任药物管理系统总经理、上市产品策略设备全球营销副总裁、市场营销–美国地区药物管理系统副总裁以及持续改进和转型副总裁。1999年8月至2005年2月期间，Hudson女士在怡安担任过各种领导职务，该公司是一家价值80亿美元的风险管理、零售、再保险和批发经纪、索赔管理、专业服务和人力资本咨询服务公司；Household International是一家在美国、英国和加拿大提供消费贷款、信用卡、汽车金融和信用保险产品的价值80亿美元的金融服务提供商。Hudson女士拥有哈佛商学院工商管理硕士学位和阿拉巴马农工大学学士学位。她被公认为2015年度彩色50大商业领袖。
- Symeria Hudson,Presently, Ms. Hudson is the President and CEO of United Way Miami. Prior to the United Way Miami role, she served as CEO of Chapman Partnership from November 2018 through July 2022. Since August 2018, Ms. Hudson has served as an Operating Advisor for Revival Healthcare Partners; as an executive Board Member and on the Governance and Audit Committee for MTF Biologics from July 2021 through December 2024 ; and as a Board Member for Baxter Foundation. From April 2016 to January 2018, Ms. Hudson was the President of Global Franchises and Innovation for ConvaTec, a $1.8 Billion international medical products and technologies company. From December 2013 to March 2016, Ms. Hudson served in various strategic leadership roles for Baxter, Inc., a $10.7 billion company that develops, manufactures, and markets products providing a broad portfolio of essential renal hospital products including home, acute and in-center dialysis; sterile IV solutions; and infusion systems and devices. Before joining Baxter, Ms. Hudson was the VP of Continuous Improvement & Transformation for Hospira, Inc (now Pfizer), a $4 billion world leader in specialty generic injectable pharmaceuticals, generic acute-care and oncology injectables, integrated infusion therapy devices and medication management solutions. From May 2005 to July 2013, Ms. Hudson served as General Manager of Medication Management Systems, VP of Global Marketing for On-Market Product Strategies Devices, VP of Marketing – US Region Medication Management Systems, and VP of Continuous Improvement and Transformation. Between August 1999 and February 2005, Ms. Hudson served in various leadership roles for Aon Corporation, an $8 billion risk management, retail, reinsurance & wholesale brokerage, claims management, specialty services, and human capital consulting services company; and Household International, an $8 billion financial service provider of consumer loans, credit cards, auto finance, and credit insurance products in the US, UK, and Canada. Ms. Hudson holds a Master of Business Administration from Harvard Business School and a BS from Alabama A&M University. She was recognized as a Top 50 Business Leader of Color in 2015.
- R. Jeffrey Bailly
-
R. Jeffrey Bailly曾于2006年10月以来担任公司主席，自1995年1月1日起担任首席执行官，总裁和董事。他于1988年加入公司，从1989年到1992年担任部门经理，从1992年到1994年担任东北运营的总经理，从1994年到1995年担任运营副总裁。从1984年到1988年他是注册会计师，受雇于Coopers & Lybrand。他是世界总裁组织（World Presidents' Organization）的成员，并在其New England Chapter的董事会工作。
R. Jeffrey Bailly has served as our Chairman since October 2006 and as Chief Executive Officer, President, and a director since January 1 1995. He joined the Company in 1988 and served as a Division Manager 1989-1992 General Manager Northeast Operations (1992-1994), and as our Vice President of Operations (1994-1995). From 1984 through 1988 Mr. Bailly, a former certified public accountant, was employed by Coopers & Lybrand. - R. Jeffrey Bailly曾于2006年10月以来担任公司主席，自1995年1月1日起担任首席执行官，总裁和董事。他于1988年加入公司，从1989年到1992年担任部门经理，从1992年到1994年担任东北运营的总经理，从1994年到1995年担任运营副总裁。从1984年到1988年他是注册会计师，受雇于Coopers & Lybrand。他是世界总裁组织（World Presidents' Organization）的成员，并在其New England Chapter的董事会工作。
- R. Jeffrey Bailly has served as our Chairman since October 2006 and as Chief Executive Officer, President, and a director since January 1 1995. He joined the Company in 1988 and served as a Division Manager 1989-1992 General Manager Northeast Operations (1992-1994), and as our Vice President of Operations (1994-1995). From 1984 through 1988 Mr. Bailly, a former certified public accountant, was employed by Coopers & Lybrand.
- Thomas Oberdorf
-
Thomas Oberdorf他是全球领先的为公司、消费者和政府提供移动和搬迁服务的提供商SIRVA, Inc.的首席财务官。他从2010年8月到2011年3月在55+市场区隔男女服装多渠道营销商Orchard Brands负责咨询工作。从2008年12月到2010年8月他是infoGROUP, Inc.的执行副总裁和首席财务官，该公司为销售线索和邮件列表、数据库营销服务、数据处理服务、电子邮件营销、市场研究、销售和营销解决方案提供业务和消费者数据库。从2006年6月到2008年他是Getty Images Inc.的高级副总裁，首席财务官和财务主管，该公司是世界领先的静态图像，视频和多媒体产品的创造者和分销商，也是公认的高端数字内容的其他形式（包括音乐）的提供者。从2002年3月到2006年6月他是CMGI, Inc.的高级副总裁，首席财务官和财务主管，该公司负责供应链管理、市场分布和电子商务解决方案，在那里他从2001年11月到2002年2月担任顾问。从1999年2月到2001年10月他是Bertelsmann AG的子公司BeMusic Direct的高级副总裁兼首席财务官，该公司是直接面向消费者的音乐销售公司。他从1981年1月到1999年1月在Readers Digest Association, Inc.担任各种职位，最近担任Global Books & Home Entertainment-Finance的副总裁。
Thomas Oberdorf is Chief Executive Officer and Chairman of SIRVA, Inc. a leading global provider of moving and relocation services to corporations, consumers and governments. From August 2010 through March 2011 Mr. Oberdorf consulted for Orchard Brands, a multi-channel marketer of men's and women's apparel for the 55+ market segment. From December 2008 through August 2010 Mr. Oberdorf was Executive Vice President and Chief Financial Officer of infoGROUP, Inc., which provides business and consumer databases for sales leads and mailing lists, database marketing services, data processing services, e-mail marketing, market research, and sales and marketing solutions. From June 2006 through 2008 Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of Getty Images Inc., the world's leading creator and distributor of still imagery, footage and multi-media products, as well as a recognized provider of other forms of premium digital content, including music. From March 2002 through June 2006 Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of CMGI, Inc., a supply chain management, marketing distribution and ecommerce solutions company, where he served as a consultant from November 2001 through February 2002. From February 1999 through October 2001 Mr. Oberdorf was Senior Vice President and Chief Financial Officer of Bertelsmann AG's subsidiary, BeMusic Direct, a direct-to-consumer music sales company. From January 1981 through January 1999 Mr. Oberdorf served in various capacities at Readers Digest Association, Inc., most recently as Vice President Global Books & Home Entertainment-Finance. - Thomas Oberdorf他是全球领先的为公司、消费者和政府提供移动和搬迁服务的提供商SIRVA, Inc.的首席财务官。他从2010年8月到2011年3月在55+市场区隔男女服装多渠道营销商Orchard Brands负责咨询工作。从2008年12月到2010年8月他是infoGROUP, Inc.的执行副总裁和首席财务官，该公司为销售线索和邮件列表、数据库营销服务、数据处理服务、电子邮件营销、市场研究、销售和营销解决方案提供业务和消费者数据库。从2006年6月到2008年他是Getty Images Inc.的高级副总裁，首席财务官和财务主管，该公司是世界领先的静态图像，视频和多媒体产品的创造者和分销商，也是公认的高端数字内容的其他形式（包括音乐）的提供者。从2002年3月到2006年6月他是CMGI, Inc.的高级副总裁，首席财务官和财务主管，该公司负责供应链管理、市场分布和电子商务解决方案，在那里他从2001年11月到2002年2月担任顾问。从1999年2月到2001年10月他是Bertelsmann AG的子公司BeMusic Direct的高级副总裁兼首席财务官，该公司是直接面向消费者的音乐销售公司。他从1981年1月到1999年1月在Readers Digest Association, Inc.担任各种职位，最近担任Global Books & Home Entertainment-Finance的副总裁。
- Thomas Oberdorf is Chief Executive Officer and Chairman of SIRVA, Inc. a leading global provider of moving and relocation services to corporations, consumers and governments. From August 2010 through March 2011 Mr. Oberdorf consulted for Orchard Brands, a multi-channel marketer of men's and women's apparel for the 55+ market segment. From December 2008 through August 2010 Mr. Oberdorf was Executive Vice President and Chief Financial Officer of infoGROUP, Inc., which provides business and consumer databases for sales leads and mailing lists, database marketing services, data processing services, e-mail marketing, market research, and sales and marketing solutions. From June 2006 through 2008 Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of Getty Images Inc., the world's leading creator and distributor of still imagery, footage and multi-media products, as well as a recognized provider of other forms of premium digital content, including music. From March 2002 through June 2006 Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of CMGI, Inc., a supply chain management, marketing distribution and ecommerce solutions company, where he served as a consultant from November 2001 through February 2002. From February 1999 through October 2001 Mr. Oberdorf was Senior Vice President and Chief Financial Officer of Bertelsmann AG's subsidiary, BeMusic Direct, a direct-to-consumer music sales company. From January 1981 through January 1999 Mr. Oberdorf served in various capacities at Readers Digest Association, Inc., most recently as Vice President Global Books & Home Entertainment-Finance.
- Marc Kozin
-
Marc Kozin自2006年以来担任公司董事。他目前在L.E.K. Consulting担任高级顾问，之前曾于1997年到2011年担任总裁。他自2002年12月以来在信息系统公司CrunchTime! Information Systems, Inc.的董事会工作，该公司为餐馆和食品服务行业提供服务。他于2012年加入Endocyte NASDAQ： ECYT（分子靶向治疗的小公司），Dyax （NASDAQ： DYAX）（集成生物科技公司）和Medical Simulation Corporation（卫生保健培训公司）的董事会。他于2013年1月加入Healthcare Royalty Partners的战略咨询委员会（Strategic Advisory Board）。他还在杜克大学（Duke University）的非盈利组织DukeEngage的董事会工作。2014年1月，他加入生命科学公司OvaScience, Inc.， （NASDAQ： OVAS）的董事会，该公司专注于新生育治疗的发现、开发和商业化。之前，Kozin先生曾从2002年12月到2005年12月在Brandwise, Inc.的董事会工作，从2002年7月到2005年3月在Lynx Therapeutics, Inc.的董事会工作，从1999年10月到2001年7月在Assurance Medical, Inc.的董事会工作。
Marc Kozin has served as a one of our directors since 2006. Mr. Kozin served as President of L.E.K. Consulting from 1997 through 2011 and as a senior Advisor from 2011 through 2018. In January 2021 Mr. Kozin joined the board of Isleworth Healthcare Acquisition Corporation Nasdaq: ISLE, a blank check company organized to effect mergers and acquisitions with businesses in the healthcare industry. In December 2020 Mr. Kozin joined the Board of Vascular Biogenics (Nasdaq: VBLT), a late stage oncology company, as Vice Chairman. In January 2019 Mr. Kozin joined the board of Dicerna Pharmaceuticals (Nasdaq: DNRA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics. In 2012 Mr. Kozin joined the board of Endocyte (Nasdaq: ECYT), a small molecule targeted therapeutic company that has since been sold to Novartis. In January 2014 Mr. Kozin joined the board of OvaScience, Inc. (Nasdaq: OVAS), a life sciences company focused on new fertility treatments that has since merged with Millendo Therapeutics. In January 2013 Mr. Kozin joined the Strategic Advisory Board of Healthcare Royalty Partners where he is Chairperson. Previously, Mr. Kozin served on the boards of directors of Dyax (sold to Shire), Frequency Therapeutics, Flex Pharma, Crunchtime! Information Systems, Medical Simulation Corporation, Brandwise, Lynx Therapeutics, Inc. and Assurance Medical, Inc. - Marc Kozin自2006年以来担任公司董事。他目前在L.E.K. Consulting担任高级顾问，之前曾于1997年到2011年担任总裁。他自2002年12月以来在信息系统公司CrunchTime! Information Systems, Inc.的董事会工作，该公司为餐馆和食品服务行业提供服务。他于2012年加入Endocyte NASDAQ： ECYT（分子靶向治疗的小公司），Dyax （NASDAQ： DYAX）（集成生物科技公司）和Medical Simulation Corporation（卫生保健培训公司）的董事会。他于2013年1月加入Healthcare Royalty Partners的战略咨询委员会（Strategic Advisory Board）。他还在杜克大学（Duke University）的非盈利组织DukeEngage的董事会工作。2014年1月，他加入生命科学公司OvaScience, Inc.， （NASDAQ： OVAS）的董事会，该公司专注于新生育治疗的发现、开发和商业化。之前，Kozin先生曾从2002年12月到2005年12月在Brandwise, Inc.的董事会工作，从2002年7月到2005年3月在Lynx Therapeutics, Inc.的董事会工作，从1999年10月到2001年7月在Assurance Medical, Inc.的董事会工作。
- Marc Kozin has served as a one of our directors since 2006. Mr. Kozin served as President of L.E.K. Consulting from 1997 through 2011 and as a senior Advisor from 2011 through 2018. In January 2021 Mr. Kozin joined the board of Isleworth Healthcare Acquisition Corporation Nasdaq: ISLE, a blank check company organized to effect mergers and acquisitions with businesses in the healthcare industry. In December 2020 Mr. Kozin joined the Board of Vascular Biogenics (Nasdaq: VBLT), a late stage oncology company, as Vice Chairman. In January 2019 Mr. Kozin joined the board of Dicerna Pharmaceuticals (Nasdaq: DNRA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics. In 2012 Mr. Kozin joined the board of Endocyte (Nasdaq: ECYT), a small molecule targeted therapeutic company that has since been sold to Novartis. In January 2014 Mr. Kozin joined the board of OvaScience, Inc. (Nasdaq: OVAS), a life sciences company focused on new fertility treatments that has since merged with Millendo Therapeutics. In January 2013 Mr. Kozin joined the Strategic Advisory Board of Healthcare Royalty Partners where he is Chairperson. Previously, Mr. Kozin served on the boards of directors of Dyax (sold to Shire), Frequency Therapeutics, Flex Pharma, Crunchtime! Information Systems, Medical Simulation Corporation, Brandwise, Lynx Therapeutics, Inc. and Assurance Medical, Inc.
- Cynthia L. Feldmann
-
Cynthia L. Feldmann， 2005年3月起担任董事，2005年12月至2011年12月担任Jetty Lane Associates（一家咨询公司）的总裁兼创始人。她是一名退休注册会计师，在两家大型全球会计师事务所拥有27年的经验。从2003年到2005年，她担任波士顿律师事务所Palmer & Dodge, LLP的生命科学业务发展官。从1994年到2002年，她是KPMG LLP的合伙人，主要担任其国家医疗技术实践的主管合伙人。从1975年到1994年，她受雇于Coopers & Lybrand（现为PricewaterhouseCoopers LLP），并在此期间被任命为其生命科学实践的负责合伙人。她拥有会计学学士学位，并持有美国公司董事学院的硕士专业董事认证。Feldmann女士曾担任HeartWare International, Inc.的董事，直到2016年8月。她曾担任Hanger, Inc.的董事，直到2018年1月。Feldmann女士是UFP Technologies, Inc.的董事、提名委员会成员和审计委员会主席，也是Frequency Therapeutics审计委员会的董事，也是Alexandria Real Estate Equities, Inc.的科学和技术委员会的董事。
Cynthia L. Feldmann,is a retired certified public accountant with a Bachelor of Science in Accounting from Boston College and 27 years of experience in two large global accounting firms. From 2005 to 2011, Ms. Feldmann served as the Founder and President of Jetty Lane Associates, a consulting firm. From 2003 to 2005, Ms. Feldmann served as the Life Sciences Business Development Officer for the Boston law firm Palmer & Dodge, LLP. From 1994 to 2002, Ms. Feldmann was a partner with KPMG LLP, primarily serving as Partner-in-Charge of its National Medical Technologies Practice. From 1975 to 1994, Ms. Feldmann was employed by Coopers & Lybrand (now PricewaterhouseCoopers LLP), and during that time was named Partner-in-Charge of its life sciences practice. Ms. Feldmann served as a director of Hanger, Inc. from 2003 until 2018, as a director of Frequency Therapeutics, Inc. from 2020 until 2023 and as a director of Alexandria Real Estate Equities, Inc. from 2022 until 2025. Ms. Feldmann has served as a director of UFP Technologies, Inc. (NASDAQ: UFPT) since 2017. - Cynthia L. Feldmann， 2005年3月起担任董事，2005年12月至2011年12月担任Jetty Lane Associates（一家咨询公司）的总裁兼创始人。她是一名退休注册会计师，在两家大型全球会计师事务所拥有27年的经验。从2003年到2005年，她担任波士顿律师事务所Palmer & Dodge, LLP的生命科学业务发展官。从1994年到2002年，她是KPMG LLP的合伙人，主要担任其国家医疗技术实践的主管合伙人。从1975年到1994年，她受雇于Coopers & Lybrand（现为PricewaterhouseCoopers LLP），并在此期间被任命为其生命科学实践的负责合伙人。她拥有会计学学士学位，并持有美国公司董事学院的硕士专业董事认证。Feldmann女士曾担任HeartWare International, Inc.的董事，直到2016年8月。她曾担任Hanger, Inc.的董事，直到2018年1月。Feldmann女士是UFP Technologies, Inc.的董事、提名委员会成员和审计委员会主席，也是Frequency Therapeutics审计委员会的董事，也是Alexandria Real Estate Equities, Inc.的科学和技术委员会的董事。
- Cynthia L. Feldmann,is a retired certified public accountant with a Bachelor of Science in Accounting from Boston College and 27 years of experience in two large global accounting firms. From 2005 to 2011, Ms. Feldmann served as the Founder and President of Jetty Lane Associates, a consulting firm. From 2003 to 2005, Ms. Feldmann served as the Life Sciences Business Development Officer for the Boston law firm Palmer & Dodge, LLP. From 1994 to 2002, Ms. Feldmann was a partner with KPMG LLP, primarily serving as Partner-in-Charge of its National Medical Technologies Practice. From 1975 to 1994, Ms. Feldmann was employed by Coopers & Lybrand (now PricewaterhouseCoopers LLP), and during that time was named Partner-in-Charge of its life sciences practice. Ms. Feldmann served as a director of Hanger, Inc. from 2003 until 2018, as a director of Frequency Therapeutics, Inc. from 2020 until 2023 and as a director of Alexandria Real Estate Equities, Inc. from 2022 until 2025. Ms. Feldmann has served as a director of UFP Technologies, Inc. (NASDAQ: UFPT) since 2017.
高管简历
中英对照 | 中文 | 英文- Christopher P. Litterio
Christopher P.Litterio于2017年11月加入公司，担任我们的第一总法律顾问兼人力资源高级副总裁。从1989年到2017年，Litterio先生在波士顿律师事务所Ruberto，Israel&Weiner，PC从事私人律师业务，专注于复杂的商业诉讼和就业法。从2005年到2017年，他担任该公司的管理合伙人，从2000年到2005年，他担任该公司诉讼部门的主席。
Christopher P. Litterio joined the Company in November 2017 as our first General Counsel and Senior Vice President of Human Resources. From 1989 until 2017 Mr. Litterio was engaged in the private practice of law at Ruberto, Israel & Weiner, PC, a Boston-based law firm, where he focused on complex business litigation and employment law. From 2005 until 2017 he served as the firm’s managing partner, and from 2000 until 2005 he was the chair of the firm’s litigation department.- Christopher P.Litterio于2017年11月加入公司，担任我们的第一总法律顾问兼人力资源高级副总裁。从1989年到2017年，Litterio先生在波士顿律师事务所Ruberto，Israel&Weiner，PC从事私人律师业务，专注于复杂的商业诉讼和就业法。从2005年到2017年，他担任该公司的管理合伙人，从2000年到2005年，他担任该公司诉讼部门的主席。
- Christopher P. Litterio joined the Company in November 2017 as our first General Counsel and Senior Vice President of Human Resources. From 1989 until 2017 Mr. Litterio was engaged in the private practice of law at Ruberto, Israel & Weiner, PC, a Boston-based law firm, where he focused on complex business litigation and employment law. From 2005 until 2017 he served as the firm’s managing partner, and from 2000 until 2005 he was the chair of the firm’s litigation department.
- Jason Holt
杰森·霍尔特，2018年加入公司任总经理，2021年6月被董事会任命为副总裁。自2023年1月起，Holt先生担任Advanced Components总经理以及MedTech首席商务官。自2024年1月起，Holt先生担任首席商务官，负责监督公司业务的开发和客户接口功能。2004-2018年，Holt先生在一家《财富》200强公司伊利诺伊机械担任过多个领导职务，最终成为该公司一个1亿+百万美元业务部门的副总裁兼总经理。
Jason Holt,joined the Company in 2018 as General Manager and in June of 2021 was appointed Vice President by the Board of Directors. Since January 2023 Mr. Holt was General Manager of Advanced Components as well as Chief Commercial Officer of MedTech. Since January 2024, Mr. Holt is Chief Commercial Officer overseeing the development and customer interfacing functions of the Company's business. From 2004-2018, Mr. Holt held a number of leadership positions at a Fortune 200 company, Illinois Tool Works, where he ultimately became Vice President and General Manager of a $100+ million business unit.- 杰森·霍尔特，2018年加入公司任总经理，2021年6月被董事会任命为副总裁。自2023年1月起，Holt先生担任Advanced Components总经理以及MedTech首席商务官。自2024年1月起，Holt先生担任首席商务官，负责监督公司业务的开发和客户接口功能。2004-2018年，Holt先生在一家《财富》200强公司伊利诺伊机械担任过多个领导职务，最终成为该公司一个1亿+百万美元业务部门的副总裁兼总经理。
- Jason Holt,joined the Company in 2018 as General Manager and in June of 2021 was appointed Vice President by the Board of Directors. Since January 2023 Mr. Holt was General Manager of Advanced Components as well as Chief Commercial Officer of MedTech. Since January 2024, Mr. Holt is Chief Commercial Officer overseeing the development and customer interfacing functions of the Company's business. From 2004-2018, Mr. Holt held a number of leadership positions at a Fortune 200 company, Illinois Tool Works, where he ultimately became Vice President and General Manager of a $100+ million business unit.
- R. Jeffrey Bailly
R. Jeffrey Bailly曾于2006年10月以来担任公司主席，自1995年1月1日起担任首席执行官，总裁和董事。他于1988年加入公司，从1989年到1992年担任部门经理，从1992年到1994年担任东北运营的总经理，从1994年到1995年担任运营副总裁。从1984年到1988年他是注册会计师，受雇于Coopers & Lybrand。他是世界总裁组织（World Presidents' Organization）的成员，并在其New England Chapter的董事会工作。
R. Jeffrey Bailly has served as our Chairman since October 2006 and as Chief Executive Officer, President, and a director since January 1 1995. He joined the Company in 1988 and served as a Division Manager 1989-1992 General Manager Northeast Operations (1992-1994), and as our Vice President of Operations (1994-1995). From 1984 through 1988 Mr. Bailly, a former certified public accountant, was employed by Coopers & Lybrand.- R. Jeffrey Bailly曾于2006年10月以来担任公司主席，自1995年1月1日起担任首席执行官，总裁和董事。他于1988年加入公司，从1989年到1992年担任部门经理，从1992年到1994年担任东北运营的总经理，从1994年到1995年担任运营副总裁。从1984年到1988年他是注册会计师，受雇于Coopers & Lybrand。他是世界总裁组织（World Presidents' Organization）的成员，并在其New England Chapter的董事会工作。
- R. Jeffrey Bailly has served as our Chairman since October 2006 and as Chief Executive Officer, President, and a director since January 1 1995. He joined the Company in 1988 and served as a Division Manager 1989-1992 General Manager Northeast Operations (1992-1994), and as our Vice President of Operations (1994-1995). From 1984 through 1988 Mr. Bailly, a former certified public accountant, was employed by Coopers & Lybrand.
- Ronald J. Lataille
Ronald J. Lataille于1997年11月加入公司担任首席财务官。加入公司之前，他从1991年到1997年10月担任Little Switzerland, Inc.的副总裁，财务主管和首席财务官。他还从1994年10月到1995年10月担任Little Switzerland的临时总裁和首席执行官。
Ronald J. Lataille joined the Company in November 1997 as our Chief Financial Officer. Prior to joining us, Mr. Lataille served as Vice President, Treasurer and Chief Financial Officer of Little Switzerland, Inc., from 1991 through October 1997. He also served as interim President and Chief Executive Officer of Little Switzerland from October 1994 through October 1995. From 1984 to 1991 Mr. Lataille, a former certified public accountant, was employed by Coopers & Lybrand.- Ronald J. Lataille于1997年11月加入公司担任首席财务官。加入公司之前，他从1991年到1997年10月担任Little Switzerland, Inc.的副总裁，财务主管和首席财务官。他还从1994年10月到1995年10月担任Little Switzerland的临时总裁和首席执行官。
- Ronald J. Lataille joined the Company in November 1997 as our Chief Financial Officer. Prior to joining us, Mr. Lataille served as Vice President, Treasurer and Chief Financial Officer of Little Switzerland, Inc., from 1991 through October 1997. He also served as interim President and Chief Executive Officer of Little Switzerland from October 1994 through October 1995. From 1984 to 1991 Mr. Lataille, a former certified public accountant, was employed by Coopers & Lybrand.
- Mitchell C. Rock
Mitchell C. Rock最初于1991年加入公司担任公司Moulded Fibre部门（现在是“Molded Fiber”）销售和营销的主管。从1999年5月到2000年10月他担任互联网新兴公司Esprocket销售和业务发展的副总裁。他于2001年4月重新加入公司担任公司Moulded Fibre部门销售和营销的副总裁，并于2002年5月起担任整个公司销售和营销的副总裁。
Mitchell C. Rock initially joined the Company in 1991 and served as Director, Sales and Marketing of our Moulded Fibre division now “Molded Fiber”. From May 1999 through October 2000 Mr. Rock served as Vice President Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined us in April 2001 as Vice President, Sales and Marketing of our Moulded Fibre division and served as our Vice President of Sales and Marketing from May 2002 to June 2014. Since June 2014 Mr. Rock has served as our Senior Vice President of Sales and Marketing. Since January1 2020 Mr. Rock also serves as General Manager, Medical. Since 2016 Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.- Mitchell C. Rock最初于1991年加入公司担任公司Moulded Fibre部门（现在是“Molded Fiber”）销售和营销的主管。从1999年5月到2000年10月他担任互联网新兴公司Esprocket销售和业务发展的副总裁。他于2001年4月重新加入公司担任公司Moulded Fibre部门销售和营销的副总裁，并于2002年5月起担任整个公司销售和营销的副总裁。
- Mitchell C. Rock initially joined the Company in 1991 and served as Director, Sales and Marketing of our Moulded Fibre division now “Molded Fiber”. From May 1999 through October 2000 Mr. Rock served as Vice President Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined us in April 2001 as Vice President, Sales and Marketing of our Moulded Fibre division and served as our Vice President of Sales and Marketing from May 2002 to June 2014. Since June 2014 Mr. Rock has served as our Senior Vice President of Sales and Marketing. Since January1 2020 Mr. Rock also serves as General Manager, Medical. Since 2016 Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.